Sunshine Biopharma shareholder consent authorizes reverse stock split of up to 1-for-20

Bitget2026/09/28 10:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sunshine Biopharma moved to enable a reverse stock split of its common stock by up to 1-for-20.
Action was authorized Sept. 15, 2026 via written consent by Dr. Steve N. Slilaty, holding about 97% of voting power.
Board gained discretion to implement the split or abandon it, setting the final whole-number ratio up to 1-for-20.
Reverse split is aimed at supporting Nasdaq’s $1.00 minimum bid requirement following recent trading below $1.00.
Shares would be rounded up to whole shares; outstanding common stock would fall from 4,310,301 to 215,515–2,155,150.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007435), on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sunshine Biopharma shareholder consent authorizes reverse stock split of up to 1-for-20

You may also like

Crypto prices